BridgeBio Pharma (BBIO) Change in Acquisitions & Divestments (2020 - 2026)

BridgeBio Pharma has disclosed Change in Acquisitions & Divestments across 7 years of filings, most recently posting $10.0 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $10.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $10.0 million (changed N/A YoY), and the FY2024 annual result was $63.2 million, down 42.81% from the prior year.
• Change in Acquisitions & Divestments came in at $10.0 million for Q1 2026 at BridgeBio Pharma, up from -$8.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $186.7 million in Q1 2022 to a low of -$265.1 million in Q3 2022.
• The 5-year median for Change in Acquisitions & Divestments is $24.4 million (2022), against an average of $16.9 million.
• Across the five-year window, Change in Acquisitions & Divestments surged 105.84% in 2023 and tumbled 213.44% in 2024, its largest moves.
• BridgeBio Pharma's Change in Acquisitions & Divestments stood at $24.0 million in 2022, then rose by 16.67% to $28.0 million in 2023, then sank by 213.44% to -$31.8 million in 2024, then jumped by 74.82% to -$8.0 million in 2025, then surged by 225.0% to $10.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $10.0 million (Q1 2026), -$8.0 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.